Processa Pharmaceuticals, Inc. Proceeds from Stock Options Exercised
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from Stock Options Exercised of $300.00 thousand for the 36-month period ending 2014-03-31, per its 10-Q filed 2014-05-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2014-05-14
- Processa Pharmaceuticals, Inc. proceeds from stock options exercised for the quarter ending 2014-03-31 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from stock options exercised for the quarter ending 2013-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from stock options exercised for the quarter ending 2013-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from stock options exercised for fiscal 2012 was $300.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month | Proceeds from Stock Options Exercised 27 month | Proceeds from Stock Options Exercised 30 month | Proceeds from Stock Options Exercised 33 month | Proceeds from Stock Options Exercised 36 month |
|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $0.00 derived: 10-Q 36 month − 10-K 33 month · filed 2014-05-14 | $0.00 derived: sum of 2 quarters · filed 2014-05-14 | $0.00 derived: sum of 3 quarters · filed 2014-05-14 | $300.00K 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | $0.00 derived: 10-K 33 month − 10-Q 30 month · filed 2014-03-27 | $0.00 derived: sum of 2 quarters · filed 2014-03-27 | $300.00K 10-K · filed 2014-03-27 | |||||
| 2013-09-30 | $0.00 derived: 10-Q 30 month − 10-Q/A 27 month · filed 2013-11-08 | $300.00K 10-Q · filed 2013-11-08 | ||||||
| 2013-06-30 | $300.00K 10-Q/A · filed 2013-09-06 | |||||||
| 2012-12-31 | $300.00K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |